1. Clinical equivalence of two tablet formulations of felodipine

   • B. P. McGrath
   • R. W. Watts
   • D. B. Elmfeldt

   Clinical Trials Pages: 169 - 172

2. Polymorphic inhibition of human angiotensin I-converting enzyme by enalaprilat

   • E. J. D. Lee

   Pharmacodynamics Pages: 173 - 175

3. The dihydropyridine calcium channel blocker BAY t 7207 attenuates the exercise induced increase in plasma ANF and cyclic GMP in patients with mildly impaired left ventricular function

   • M. Kentsch
   • G. Müller-Esch
   • V. Peinke

   Pharmacodynamics Pages: 177 - 182

4. Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects

   • H. V. Semlitsch
   • P. Anderer
   • B. Saletu

   Pharmacodynamics Pages: 183 - 191

5. Renal and endocrine effects of flosulide, after single and repeated administration to healthy volunteers

   • P. Brunel
   • M. Turri
   • A. Sioufi

   Pharmacodynamics Pages: 193 - 201

6. Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients

   • A. H. J. Scaf
   • H. Wesseling
   • P. H. J. M. Dunselman

   Pharmacokinetics and Disposition Pages: 203 - 210

7. 4-Methylpyrazole monitoring during haemodialysis of ethylene glycol intoxicated patients

   • H. Faessel
   • J. M. Scherrmann
   • F. J. Baud

   Pharmacokinetics and Disposition Pages: 211 - 213

8. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals

   • I. Walter-Sack
   • J. X. de Vries
   • A. Voss

   Pharmacokinetics and Disposition Pages: 215 - 220

9. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment

   • R. H. Barbhaiya
   • D. S. Greene
   • U. A. Shukla

   Pharmacokinetics and Disposition Pages: 221 - 228

10. Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function

    • R. H. Barbhaiya
    • M. E. Brady
    • D. S. Greene

    Pharmacokinetics and Disposition Pages: 229 - 235

11. Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation

    • P. A. Thürmann
    • C. Sonnenburg-Chatzopoulos
    • R. Lissner

    Pharmacokinetics and Disposition Pages: 237 - 242

12. The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA:Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers

    • R. W. Peck
    • R. Wiggs
    • J. Posner

    Pharmacokinetics and Disposition Pages: 243 - 249

13. Announcements

    Announcement Pages: 250 - 250